# Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite

> **NCT04401527** · PHASE2 · WITHDRAWN · sponsor: **Hope Pharmaceuticals**

## Conditions studied

- COVID-19
- Acute Respiratory Distress Syndrome
- Acute Respiratory Failure

## Interventions

- **DRUG:** Sodium Nitrite
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT04401527
- **Lead sponsor:** Hope Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-07-22
- **Primary completion:** 2020-08-15
- **Final completion:** 2020-08-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No recruitment
- **Last updated:** 2020-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04401527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04401527, "Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT04401527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*